Combination therapy improves site-specific BMD vs. teriparatide & denosumab monotherapies
How to Cite
OrthoEvidence. Combination therapy improves site-specific BMD vs. teriparatide & denosumab monotherapies. ACE Report. 2017;6(1):23. Available from: https://myorthoevidene.com/AceReport/Report/9177
Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled TrialJ Clin Densitom. 2016 Jul-Sep;19(3):346-51
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
94 postmenopausal osteoporotic women were randomized to receive either 60mg denosumab subcutaneously every 6 months, 20ug teriparatide subcutaneously daily, or a combination treatment of both 60mg denosumab and 20ug teriparatide for a duration of 24 months. The purpose of this study was to compare the individual response rates of the three treatment groups in terms of increases in bone mineral den...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE